Nolatrexed is a thymidylate synthase inhibitor.[1][2]

References

  1. ^ Hughes AN, Rafi I, Griffin MJ, et al. (January 1999). "Phase I studies with the nonclassical antifolate nolatrexed dihydrochloride (AG337, THYMITAQ) administered orally for 5 days". Clin. Cancer Res. 5 (1): 111–8. PMID 9918208.
  2. ^ "Nolatrexed". PubChem.gov. Pub Chem. Retrieved 12 August 2014.


No tags for this post.